Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...

Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...

As Incyte strives to push its topical JAK inhibitor Opzelura into additional dermatology indications, the company’s latest ...

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream ...

OPZELURA (ruxolitinib cream) has shown strong market growth, driven by increasing adoption in dermatological conditions like vitiligo and atopic dermatitis. Its unique positioning as the first ...

Incyte INCY announced positive results from two late-stage studies evaluating the safety and efficacy of its twice-daily ...

The 2021-approved Opzelura grew sales by 50% during 2024, reaching $508 million on the back of its two approved indications in atopic dermatitis and vitiligo. Included in the fourth quarter’s $ ...

Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting ...

Opzelura is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age ...

It is facing competition in the category from non-steroid drugs like Incyte’s JAK inhibitor Opzelura (ruxolitinib), approved for atopic dermatitis in 2021, although, that requires twice-daily ...

Opzelura 2025 net product revenue is expected between $630 million and $670 million, supported by demand growth in atopic dermatitis and vitiligo, contributions from Europe, and the potential ...

In dermatology, we see strong potential for a topical version of the active ingredient in Jakafi (ruxolitinib), which was approved in 2021 in atopic dermatitis as Opzelura and received a label ...